Functional CD4+ and CD8+ T-cell responses induced by autologous mitomycin C treated Epstein-Barr virus transformed lymphoblastoid cell lines

被引:6
作者
Meij, P [1 ]
Bloemena, E [1 ]
Palmen, N [1 ]
Brink, A [1 ]
Vervoort, MBHJ [1 ]
Meijer, CJLM [1 ]
Middeldorp, JN [1 ]
机构
[1] Univ Hosp Vrije Univ, Dept Pathol, NL-1007 MB Amsterdam, Netherlands
关键词
Epstein-Barr virus; posttransplant lymphoproliferative disorders; T-cell; mitomycin C; immunotherapy;
D O I
10.1006/cimm.2001.1760
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Epstein-Barr virus (EBV) gene expression in tumor cells of posttransplant lymphoproliferative disorder (PTLD) patients resembles that of EBV transformed B-cell lines (LCL). EBV-specific cytotoxic T-lymphocytes can be generated by stimulating peripheral blood lymphocytes with autologous LCL. We describe a standardized method for the growth inactivation and cryopreservation of LCL for optimal T-cell stimulation and analyzed the function and phenotype of responding T-cells. LCL growth was completely blocked by mitomycin C treatment (McLCL) and McLCL could be cryopreserved while retaining excellent APC function. McLCL stimulated both CD4(+) and CD8(+) T-cells as measured by HLA-DR and CD25 expression using FACS analysis. EBV-specific CTL activity and T-cell proliferation were induced and immunocytochemical staining showed CD4(+) and (granzyme B positive) CD8(+) T-cells resetting with McLCL. Granzymes A and B, IFN-gamma, and IL-6 were detected at significant levels in the supernatant. Thus, ex vivo T-cell activation with cryopreserved McLCL results in activation of both CD4(+) and CD8(+) T-cells producing a Th1-like cytokine profile, making this a suitable protocol for adoptive therapy of PTLD. (C) 2001 Academic Press.
引用
收藏
页码:25 / 33
页数:9
相关论文
共 32 条
[1]  
[Anonymous], 1996, Fields virology
[2]  
Brosterhus H, 1999, EUR J IMMUNOL, V29, P4053, DOI 10.1002/(SICI)1521-4141(199912)29:12<4053::AID-IMMU4053>3.3.CO
[3]  
2-3
[4]   Immunology - Deficient cellular immunity - Finding and fixing the defects [J].
Greenberg, PD ;
Riddell, SR .
SCIENCE, 1999, 285 (5427) :546-551
[5]   Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease:: prophylactic infusion of EBV-specific cytotoxic T cells [J].
Gustafsson, Å ;
Levitsky, V ;
Zou, JZ ;
Frisan, T ;
Dalianis, T ;
Ljungman, P ;
Ringden, O ;
Winiarski, J ;
Ernberg, I ;
Masucci, MG .
BLOOD, 2000, 95 (03) :807-814
[6]  
Haque T, 1998, J IMMUNOL, V160, P6204
[7]   The role of adoptive immunotherapy in the prevention and treatment of lymphoproliferative disease following transplantation [J].
Haque, T ;
Crawford, DH .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 106 (02) :309-316
[8]   Role of donor versus recipient type Epstein-Barr virus in post-transplant lymphoproliferative disorders [J].
Haque, T ;
Crawford, DH .
SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 1998, 20 (3-4) :375-387
[9]   The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses [J].
Kalams, SA ;
Walker, BD .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (12) :2199-2204
[10]   Epstein-Barr virus-specific cytotoxic T cell responses in HIV-1 infection - Different kinetics in patients progressing to opportunistic infection or non-Hodgkin's lymphoma [J].
Kersten, MJ ;
Klein, MR ;
Holwerda, AM ;
Miedema, F ;
vanOers, MHJ .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (07) :1525-1533